The Pharmacology and Clinical Use of Methotrexate

New England Journal of Medicine

Volumn 309, Issue 18, 1983, Pages 1094-1104

  Jolivet, Jacques ^a   Cowan, Kenneth H ^a   Curt, Gregory A ^a   Clendeninn, Neil J ^a   Chabner, Bruce A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; FLUOROURACIL; METHOTREXATE; TIOGUANINE; VINCRISTINE;

ADVERSE DRUG REACTION; BIOAVAILABILITY; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CLINICAL STUDY; DIGESTIVE SYSTEM; DRUG DOSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INTOXICATION; KIDNEY; NEPHROTOXICITY; NERVOUS SYSTEM; NEUROTOXICITY; PHARMACOKINETICS; PHARMACOLOGY; PLEURISY; RESPIRATORY SYSTEM; REVIEW; SKIN TOXICITY; SURVEY; THERAPY; VISUAL SYSTEM;

EID: 0020554087     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198311033091805     Document Type: Review

References (155)

1. Chabner B, ed. pharmacologic principles of cancer treatment. Philadelphia: WB Saunders 1982:229–255.
2. Weinstein GD. Methotrexate. Ann Intern Med 1977; 86: 199–204.
3. Blume KG. Beutler E, Brass KJ, et al. Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 1980; 302: 1041–1046.
4. Willkens RF, Watson MA. Methotrexate: a perspective of its use in the treatment of rheumatic diseases. J Lab Clin Med 1982; 100: 314–321.
5. McGuire JJ, Hsieh P. Coward JK, Bertino JR. Enzymatic synthesis of folylpolyglutamates: characterization of the reaction and its products. J Biol Chem 1980; 255: 5776–5788.
6. McGuire JJ, Bertino JR. Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem 1981; 38: 19–48.
7. Werkheiser WC. The biochemical, cellular, and pharmacological action and effects of the folic acid antagonists. Cancer Res 1963; 23: 1277–1285.
8. Farber S, Diamond LK, Mercer RD, Sylvester RF Jr., Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948; 238: 787–793.
9. Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem 1978; 243: 5007–5017.
10. Bender RA. Membrane transport of methotrexate in human neoplastic cells. Cancer Chemother Rep 1975; 6: 73–82.
11. Schilsky RL, Bailey BD, Chabner BA. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol 1981;30: 1537–1542.
12. Warren RD, Nichols AP, Bender RA. Membrane transport of methotrexate in human lymphoblastoid cells. Cancer Res 1978; 38: 668–671.
13. Hill BT, Bailey BD, White JC, Goldman ID. Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate. Cancer Res 1979; 39: 2440–2446.
14. de Jager R, Dupont D, Rodzynek J-J, Dorlet C, Lagrange G. Phase I clinical trial and pharmacology of 2,4-diammino-5-(3′4′-dichlorophenyl)6-methylpyrimidine (metoprine) and folinic acid. Cancer Chemother Pharmacol 1981;6: 75–80.
15. de Jager R, Brugarolas A, Hansen M. Phase II clinical trial of DDMP (2,4diammino–5-(3′4′-dichlorophenyl)-6-methylpyrimidine) and folinic acid in solid tumors. Cancer Chemother Pharmacol 1981; 6: 81–84.
16. Moran RG, Mulkins M. Heidelberger C. Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. Proc Natl Acad Sci USA 1979; 76: 5924–5928.
17. White JC, Goldman ID. Methotrexate resistance in an L1210 cell line resulting from increased dihydrofolate reductase, decreased thymidylate synthetase activity, and normal membrane transport: computer simulations based on network thermodynamics. J Biol Chem 1981; 256: 5722–5727.
18. Ayusawa D, Koyama H, Seno T. Resistance to methotrexate in thymidylate synthetase-deficient mutants of cultured mouse mammary tumor FM3A cells. Cancer Res 1981;41: 1497–1501.
19. Washtien WL. Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells. Mol Pharmacol 1982; 21: 723–728.
20. Cohen M, Bender RA, Donehower RC, Myers CE, Chabner BA. Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells. Cancer Res 1978; 38: 2866–2870.
21. White JC, Loftfield S, Goldman ID. The mechanism of action of methotrexate. III. Requirement of free intracellular methotrexate for maximal suppression of [l4C)formate incorporation into nucleic acids and protein. Mol Pharmacol 1975; 11: 287–297.
22. White JC. Reversal of methotrexate binding to dihydrofolate reductase by dihydrofolate: studies with pure enzyme and computer modeling using network thermodynamics. J Biol Chem 1979; 254: 10889–10895.
23. Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 1973; 52: 1804–1811.
24. Smith GK, Benkovic PA, Benkovic SJ. L(—)-10formyltetrahydrofolate is the cofactor for glycinamide ribonucleotide transformylase from chicken liver. Biochemistry 1981; 20: 4034–4036.
25. Zaharko DS, Fung W-P, Yang K-H. Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Res 1977; 37: 1602–1607.
26. Baugh CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 1973; 52: 27–34.
27. Jacobs SA, Derr CJ, Johns DG. Accumulation of methotrexate diglutamate in human liver during methotrexate therapy. Biochem Pharmacol 1977; 26: 2310–2313.
28. Whitehead VM, Perrault MM, Stelcner S. Tissue-specific synthesis of methotrexate polyglutamates in the rat. Cancer Res 1975; 35: 2985–2990.
29. Whitehead VM. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells. Cancer Res 1977; 37: 408–412.
30. Rosenblatt DS, Whitehead VM, Dupont MM, Vuchich M-J, Vera N. Synthesis of methotrexate polyglutamates in cultured human cells. Mol Pharmacol 1978; 14: 210–214.
31. Poser RG, Sirotnak FM, Chello PL. Extracellular recovery of methotrexate-polyglutamates following efflux from L1210 leukemia cells. Biochem Pharmacol 1980; 29: 2701–2704.
32. Poser Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res 1981; 41: 4441–4446.
33. Witte A, Whitehead VM, Rosenblatt DS, Vuchich M-J. Synthesis of methotrexate polyglutamates by bone marrow cells from patients with leukemia and lymphoma. Dev Pharmacol Ther 1980; 1: 40–46.
34. Gewirtz DA, White JC, Randolph JK, Goldman ID. Transport, binding, and polyglutamation of methotrexate in freshly isolated rat hepatocytes. Cancer Res 1980; 40: 573–578.
35. Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 1980; 17: 105–110.
36. Fry DW, Yalowich JC, Goldman ID. Rapid formation of poly-y-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem 1982; 257: 1890–1896.
37. Krakower GR, Nylen PA, Kamen BA. Separation and identification of subpicomole amounts of methotrexate polyglutamates in animal and human biopsy material. Anal Biochem 1982; 122: 412–416.
38. Schilsky RL, Bailey BD, Chabner BA. Methotrexate polyglutamate synthesis by cultured human breast cancer cells. Proc Natl Acad Sci USA 1980;77: 2919–2922.
39. Jolivet J, Schilsky RL, Bailey BD, Chabner BA. The synthesis and retention of methotrexate polyglutamates in cultured human breast cancer cells. Ann NY Acad Sci 1982; 397: 184–192.
40. Jolivet J, Schilsky RL, Bailey BD, Drake JC, Chabner BA. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest 1982; 70: 351–360.
41. Jolivet J, Chabner BA. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells: selective retention and less dissociable binding of 4–NH2–10-CH5-PteGlu4 and 5 to dihydrofolate reductase. J Clin Invest (in press).
42. Jacobs SA, Adamson RH, Chabner BA, Derr CJ, Johns DG. Stoichiometric inhibition of mammalian dihydrofolate reductase by the y-glutamyl metabolite of methotrexate: 4-amino-4-deoxy-Nm-methylpteroylglutamyl-y-glutamate. Biochem Biophys Res Commun 1975; 63: 692–698.
43. Clendeninn NJ, Cowan KH, Kaufman BT, Nadkarni MV, Chabner BA. Dihydrofolate reductase from a methotrexate-resistant human breast cancer cell line: purification, properties, and binding of methotrexate and polyglutamates. Proc Am Assoc Cancer Res 1983; 24: 276. abstract.
44. Rosenblatt DS, Whitehead VM, Vera N, Pottier A, Dupont M, Vuchich M-J. Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells. Mol Pharmacol 1978; 14: 1143–1147.
45. Balinska M, Galivan J, Coward JK. Efflux of methotrexate and its polyglutamate derivatives from hepatic cells in vitro. Cancer Res 1981; 41: 2751–2756.
46. Szeto DW, Cheng Y, Rosowsky A, et al. Human thymidylate synthetase. III. Effect of methotrexate and methotrexate analogs. Biochem Pharmacol 1977; 28: 2633–2637.
47. Baggott JE. Inhibition of purified avian liver aminoimidazole–carboxamide ribotide transformylase by polyglutamates of methotrexate and oxidized folates. Fed Proc 1983; 42: 667. abstract.
48. Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res 1981; 41: 4447–4452.
49. Hanggi UJ, Littlefield JW. Isolation and characterization of the multiple forms of dihydrofolate reductase from methotrexate-resistant hamster cells. J Biol Chem 1974; 249: 1390–1397.
50. Flintoff WF, Essani K. Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochemistry 1980; 19: 4321–4327.
51. Haber DA, Beverley SM, Kiely ML, Schimke RT. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. J Biol Chem 1981; 256: 9501–9510.
52. Melera PW, Lewis JA, Biedler JL, Hession C. Antifolate-resistantChinese hamster cells: evidence for dihydrofolate reductase gene amplification among independently derived sublines overproducing different dihydrofolate reductases. J Biol Chem 1980; 255: 7024–7028.
53. Goldie JH, Krystal G, Hartley D, Gudauskas G, Dedhar S. A methotrexate insensitive variant of folate reductase present in two lines of methotrexateresistant L5178Y cells. Eur J Cancer 1980; 16: 1539–1546.
54. Jackson RC, Niethammer D. Acquired methotrexate resistance in lymphoblasts resulting from altered kinetic properties of dihydrofolate reductase. Eur J Cancer 1977; 13: 567–575.
55. Dedhar S, Freisheim JH, Hynes JB, Goldie JH. Inhibition of a methotrexate-sensitive dihydrofolate reductase from L5178Y cells by substituted triazines and quinazolines. Biochem Pharmacol 1983; 32: 922–924.
56. Harding NGL, Martelli MF, Huennekens FM. Amethopterin-induced changes in the multiple forms of dihydrofolate reductase from L1210 cells. Arch Biochem Biophys 1970; 137: 295–296.
57. Albrecht AM, Biedler JL, Hutchison DJ. Twodifferent species of dihydrofolate reductase in mammalian cells differentially resistant to amethopterin and methasquin. Cancer Res 1972; 32: 1539–1546.
58. Nakamura H, Littlefield JW. Purification, properties, and synthesis of dihydrofolate reductase from wild type and methotrexate-resistant hamster cells. J Biol Chem 1972; 247: 179–187.
59. Littlefield JW. Hybridization of hamster cells with high and low folate reductase activity. Proc Natl Acad Sci USA 1969; 62: 88–95.
60. Fischer GA. Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells. Biochem Pharmacol 1961; 7: 75–77.
61. Hakala MT, Zakrzewski SF, Nichol CA. Relation of folic acid reductase to amethopterin resistance in cultured mammalian cells. J Biol Chem 1961; 236: 952–958.
62. Biedler JL, Albrecht AM, Hutchison DJ, Spengler BA. Drug response, dihydrofolate reductase, and cytogenetics of amethopterin-resistant Chinese hamster cells in vitro. Cancer Res 1972; 32: 153–161.
63. Biedler JL, Albrecht AM, Spengler BA. Biochemical and karyological properties of cells resistant to the quinazoline antifolate, methasquin. Eur J Cancer 1978; 14: 41–49.
64. Bostock CJ, Clark EM, Harding NGL, et al. The development of resistance to methotrexate in a mouse melanoma cell line. I. Characterisation of the dihydrofolate reductases and chromosomes in sensitive and resistant cells. Chromosoma 1979; 74: 153–177.
65. Jackson RC, Niethammer D. Huennekens FM. Enzymic and transport mechanisms of amethopterin resistance in L1210 mouse cells. Cancer Biochem Biophys 1975; 1: 151–155.
66. Lindquist CA, Moroson BA, Bertino JR. A methotrexate resistant subline of L1210 characterized by impaired transport of methotrexate, but not 5-methyl tetrahydrofolate. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1978; 19: 165. abstract.
67. Flintoff WF, Davidson SV, Siminovitch L. Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells. Somatic Cell Genet 1976; 2: 245–261.
68. Biedler JL, Spengler BA. Metaphase chromosome anomaly: association with drug resistance and cell-specific products. Science 1976; 191: 185–187.
69. Alt FW, Kellems RE, Schimke RT. Synthesis and degradation of folate reductase in sensitive and methotrexate-resistant lines of S-180 cells. J Biol Chem 1976; 251: 3063–3074.
70. Hänggi UJ, Littlefield JW. Altered regulation of the rate of synthesis of dihydrofolate reductase in methotrexate-resistant hamster cells. J Biol Chem 1976; 251: 3075–3080.
71. Kellems RE, Alt FW, Schimke RT. Regulation of folate reductase synthesis in sensitive and methotrexate-resistant sarcoma 180 cells: in vitro translation and characterization of folate reductase mRNA. J Biol Chem 1976; 251: 6987–6993.
72. Chang SE, Littlefield JW. Elevated dihydrofolate reductase messenger mRNA levels in methotrexate-resistant BHK cells. Cell 1976; 7: 391–396.
73. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 1978; 253: 1357–1370.
74. Morandi C, Attardi G. Isolation and characterization of dihydrofolate acid reductase from methotrexate-sensitive and -resistant human cell lines. J Biol Chem 1981; 256: 10169–10175.
75. Domin BA, Cheng Y, Hakala MT. Properties of dihydrofolate reductase from a methotrexate-resistant subline of human KB cells and comparison with enzyme from KB parent cells and mouse S180 AT/3000 cells. Mol Pharmacol 1982; 21: 231–238.
76. Cowan KH, Goldsmith ME, Levine RM, et al. Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem 1982; 257: 15079–15086.
77. Kaufman RJ, Brown PC, Schimke RT. Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes. Proc Natl Acad Sci USA 1979; 76: 5669–5673.
78. Curt GA, Carney DN, Cowan KH, et al. Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med 1983; 308: 199–202.
79. Cowan KH, Jolivet J. A novel mechanism of resistance to methotrexate in human breast cancer cells: lack of methotrexate polyglutamate formation. Clin Res 1983; 31: 508a.
80. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetics. J Pharm Sci 1971; 60: 1128–1133.
81. Pinedo HM, Zaharko DS, Bull J, Chabner BA. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res 1977; 37: 445–450.
82. Eichholtz H, Trott K-R. Effect of methotrexate concentration and exposure time on mammalian cell survival in vitro. Br J Cancer 1980; 41: 277–284.
83. Bertino JR, Fischer GA. Techniques for study of resistance to folic acid antagonists. Methods Med Res 1964; 10: 297–307.
84. Myers CE, Lippman ME, Eliot HM. Competitive protein binding assay for methotrexate. Proc Natl Acad Sci USA 1975; 72: 3683–3686.
85. Bertino JR, Isacoff WH. Methods of measuring methotrexate in body fluids. In: Pinedo HM, ed. Clinical pharmacology of antineoplastic drugs. Amsterdam: Elsevier/North Holland, 1978:3–11.
86. Oellerich M, Engelhardt P, Schaadt M, Diehl V. Determination of methotrexate in serum by a rapid, fully mechanized enzyme in immunoassay (EMIT). J Clin Chem Clin Biochem 1980; 18: 169–174.
87. Canfell C, Sadée W. Methotrexate and 7-hydroxymethotrexate: serum level monitoring by high-performance liquid chromatography. Cancer Treat Rep 1980; 64: 165–169.
88. Craft AW, Rankin A, Aherne W. Methotrexate absorption in children with acute lymphoblastic leukemia. Cancer Treat Rep 1981; 65: Supplement 1: 77–81.
89. Kearney PJ, Light PA, Preece A, Mott MG. Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 1979; 3: 117–120.
90. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res 1983; 43: 2342–2345.
91. Pinkerton CR, Welshman SG, Kelly JG, Shanks RG, Bridges JM. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1983; 10: 36–39.
92. Smith DK, Omura GA, Ostroy F. Clinical pharmacology of intermediatedose oral methotrexate. Cancer Chemother Pharmacol 1980; 4: 117–120.
93. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293: 161–166.
94. Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 1974; 34: 3487–3491.
95. Bode U, Magrath IT, Bleyer WA, Poplack DG, Glaubiger DL. Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res 1980;40: 2184–2187.
96. Nelson RW, Frank JT. Intrathecal methotrexate-induced neurotoxicities. Am J Hosp Pharm 1981; 38: 65–68.
97. Freeman AI, Weinberg V, Brecher ML, et al. Comparison of intermediatedose methotrexate with cranial irradiation for the post-incubation treatment of acute lymphocytic leukemia in children. N Engl J Med 1983; 308: 477–484.
98. Evans WE, Hutson PR, Stewart CF, et al. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther 1983; 33: 301–307.
99. Echelberger CK, Riccardi R, Bleyer A, Levine AS. Poplack DG. Influence of body position on ventricular cerebrospinal fluid methotrexate concentration following intralumbar administration. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1981; 22: 365. abstract.
100. Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 1979;205: 1135–1137.
101. Bowen D, White JC, Goldman ID. Basis for fluoropyrimidine-induced antagonism to methotrexate in Ehrlich ascites tumor cells in vitro. Cancer Res 1978; 38: 219–222.
102. Capizzi RL. Schedule-dependent synergism and antagonism between methotrexate and asparaginase. Biochem Pharmacol 1974; 23: Supplement 2: 151–161.
103. Capizzi RL. Asparaginase-methotrexate in combination chemotherapy: scheduledependent differential effects on normal versus neoplastic cells. Cancer Treat Rep 1981; 65: Supplement 4: 115–121.
104. Cadman E, Eiferman P. Mechanism of syncrgistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. J Clin Invest 1979; 64: 788–797.
105. Bender RA, Nichols AP, Norton L, Simon RM. Lack of therapeutic synergism between vincristine and methotrexate in LI210 murine leukemia in vivo. Cancer Treat Rep 1978; 62: 997–1003.
106. Armstrong RD, Vera R, Synder P, Cadman E. Enhancement of 6-thioguanine cytotoxic activity with methotrexate. Bicohem Biophys Res Commun 1982; 109: 595–601.
107. Kim K, Blechman WJ, Riddle VGH, Pardee AB. Basis of observed resistance of L1210 leukemia in mice methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, 1-β-D-arabinofuranosylcytosine administered in different concentrations. Cancer Res 1981;41: 4529–4534.
108. Hamel E, Johnson G, Glaubiger D. Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N?-methyltetrahydrofolate. Cancer Treat Rep 1981; 65: 545–553.
109. Kano Y, Sakamoto S. Sakuraya K, et al. Effect of nitrous oxide on human cell lines. Cancer Res 1983; 43: 1493–1496.
110. Dudman NPB, Slowiaczek P, Tattersall MHN. Methotrexate rescue by 5-methyltetrahydrofolate or 5-formyltetrahydrofolate in lymphoblast cell lines. Cancer Res 1982; 42: 502–507.
111. Schrecker AW, Mead JAR, Greenberg WH, Goldin A. Dihydrofolate reductase activity of leukemia L1210 during development of methotrexate resistance. Biochem Pharmacol 1971; 20: 716–718.
112. Mehta BM, Glass JP. Shapiro WR. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Res 1983; 43: 435–438.
113. Frei E III, Jaffe N, Tattersall MHN, Pitman S, Parker L. New approaches to cancer chemotherapy with methotrexate. N Engl J Med 1975; 292: 846–851.
114. Jacobs SA, Stoller RG, Chabner BA, Johns DG. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 1976; 57: 534–538.
115. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 630–634.
116. Nirenberg A, Mosende C, Mehta BM. Gisolfi AL. Rosen G. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 1977; 61: 779–783.
117. Isacoff WH, Morrison PF, Aroesty J, Willis KL, Block JB, Lincoln TL. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 1977; 61: 1665–1674.
118. Tattersall MHM, Parker LM, Pitman SW, Frei E. Clinical pharmacology of high-dose methotrexate. Cancer Treat Rep 1975; 6: 25–29.
119. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate: early recognition of high-risk patients. Cancer Chemother Pharmacol 1979; 3: 161–166.
120. Monjanel S, Rigault JP, Cano JP, Carcassonne Y, Favre R. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol 1976; 3: 189–196.
121. Kerr IG, Jolivet J, Collins JM, Drake JC, Chabner BA. Test dose for predicting high-dose methotrexate infusions. Clin Pharmacol Ther 1983; 33: 44–51.
122. Frei E III, Blum RH, Pitman SW, et al. High-dose methotrexate with leucovorin rescue: rationale and spectrum of antitumor activity. Am J Med 1980; 68: 370–376.
123. Djerassi I, Kim JS, Nayak NP, Ohanissian H, Adler S. High-dose methotrexate with citrovorum factor rescue: a new approach to cancer chemotherapy. In: Tagnon HJ. Staquet MJ, eds. Recent advances in cancer treatment. Vol. 3. New York: Raven Press, 1977:201–225.
124. Isacoff WH, Eilber F, Tabbarah H, et al. Phase II clinical trial with highdose methotrexate therapy and citrovorum factor rescue. Cancer Treat Rep 1978;62: 1295–1304.
125. Jaffe N, Frei E III, Traggis D, Watts H. Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases. Cancer 1977; 39: 45–50.
126. Pratt CB, Howarth C, Ransom JL, et al. High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma. Cancer Treat Rep 1980; 64: 11–20.
127. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huyos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163–2177.
128. Jaffe N, Frei E III, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1971; 291: 994–997.
129. Rosenberg SA, Chabner BA, Young RC, et al. Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat Rep 1979; 63: 739–751.
130. Edmonson JH, Green SJ, Wins JC, et al. Methotrexate as adjuvant treatment for primary osteosarcoma. N Engl J Med 1980; 303: 642–643.
131. Jaffe N, Link MP, Cohen D, et al. High-dose methotrexate in osteogenic sarcoma. Natl Cancer Inst Monogr 1981; 56: 201–206.
132. Mead GM, Jacobs C. Changing role of chemotherapy in treatment of head and neck cancer. Am J Med 1982; 73: 582–595.
133. Hong WK, Bromer R. Chemotherapy in head and neck cancer. N Engl J Med 1983; 308: 75–79.
134. Levitt M, Mosher MB, DeConti RC. et al. Improved therapeutic index of methotrexate with “leucovorin rescue.” Cancer Res 1973; 33: 1729–1734.
135. Woods RL, Fox RM, Tattersall MHN. Methotrexate treatment of squamous-cell head and neck cancers: dose–response evaluation. Br Med J 1981;282: 600–602.
136. Kirkwood JM, Canellos GP, Ervin TJ, Pitman SW, Weichselbaum R, Miller D. Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective program. Cancer 1981; 47: 2414–2421.
137. DeConti RC. Schoenfeld D. A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer 1981; 48: 1061–1072.
138. Ettinger DS, Stanley KE, Nystrom JS. Phase II study of high-dose methotrexate in the treatment of patients with non-small carcinoma of the lung: an Eastern Cooperative Oncology Group Study. Cancer Treat Rep 1980; 64: 1017–1021.
139. Ihde DC, Johnson-Early A, Carney DN, et al. Lack of efficacy of highdose methotrexate by 30-hour infusion in patients with progressive small cell carcinoma of the lung. Cancer Treat Rep 1982; 66: 1223–1225.
140. Hande KR, Oldham RK, Fer MF, Richardson RL, Greco FA. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med 1982; 73: 413–419.
141. Sweet DL, Golomb HM, Ultmann JE, et al. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 1980; 92: 785–790.
142. Fisher RF. DeVita VT Jr., Hubbard SM, et al. Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983; 98: 304–309.
143. Skarin AT, Canellos GP, Rosenthal DS, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1: 91–98.
144. Abelson HT, Fasburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983; 1: 208–216.
145. Doroshow JH, Locker GY, Gaasterland DE, Hubbard SP, Young RC, Myers CE. Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film. Center 1981; 48: 2158–2162.
146. Doyle LA, Berg C, Bottino G, Chabner BA. Erythema and desquamation after high-dose methotrexate. Ann Intern Med 1983; 98: 611–612.
147. Urban C, Nirenberg A, Caparros B, Anac S, Cacavio A, Rosen G. Chemical pleuritis as the cause of acute chest pain following high-dose methotrexate treatment. Cancer 1983; 51: 34–37.
148. Shamberger RC, Rosenberg SA, Seipp CA, Sherins RJ. Effects of highdose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep 1981; 65: 739–746.
149. Hill BT, Dedhar S, Goldie JH. Evidence that at “high” extracellular methotrexate concentrations the transport barrier is unlikely to be an important mechanism of drug resistance. Biochem Pharmacol 1982; 31: 263–266.
150. Bertino JR, Cashmore A, Fink M, Calabresi P, Lefkowitz E. The “induction” of leucocyte and erythrocyte dihydrofolate reductase by methotrexate. II. Clinical and pharmacologic studies. Clin Pharmacol Ther 1965; 6: 763–770.
151. Domin BA, Grill SP, Bastow KF, Cheng Y-C. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells. Mol Pharmacol 1982; 21: 478–482.
152. Jolivet J, Levine RM, Cowan KH. The regulation of dihydrofolate reductase in gene-amplified methotrexate-resistant human breast cancer cells. Clin Res 1983; 3L: 509A. abstract.
153. Sirotnak FM, Moccio DM, Dorick DM. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 1978; 38: 345–353.
154. Galivan J, Nimec Z. Effects of folinic acid on hepatoma cells containing methotrexate polyglutamates. Cancer Res 1983; 43: 551–555.
155. Stoller RG, Kaplan HG, Cummings FJ, Calabresi P. A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue. Cancer Res 1979; 39: 908–912.